Board approves final dividend of Rs. 20/- per share, subject to approval of shareholders in the ensuing 48th AGM
GLAND · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 17.4 pts more than Nifty Smallcap 250 and 16.6 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Gland Pharma's Board has approved a final dividend of Rs. 20 per equity share (2000% on face value of Rs. 1) for FY 2025-26, pending shareholder approval at the 48th AGM on August 25, 2026. For the full year, consolidated revenue grew 14.5% to Rs. 64,307 million, while profit after tax rose 20% to Rs. 4,373 million. EPS improved significantly from Rs. 42.40 to Rs. 62.35. The company reported an exceptional item of Rs. 243.46 million due to provisioning for new labour code compliance. Statutory auditors Deloitte Haskins & Sells issued an unmodified (clean) opinion on the annual financials. Record date for dividend is August 11, 2026.
The 20% PAT growth and clean audit signal financial health, while the Rs. 20 dividend demonstrates strong cash generation and commitment to shareholder returns. The substantial EPS improvement could support stock price appreciation.